Ivermectin (22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b) is a broad-spectrum antiparasitic medication. It is traditionally used against worms, but more recently found to be effective against mites and some lice too. Ivermectin is currently being used to help eliminate river blindness (onchocerciasis) in the Americas and stop transmission of lymphatic filariasis around the world.
A new study describes the nature and extent of the shift in dispensing these medications, as well as its eventual outcome.
A treatment combining two antibodies (casirivimab and imdevimab) is recommended for two specific groups of patients with covid-19 by a WHO Guideline Development Group (GDG) panel of international experts and patients in The BMJ today.
Earlier this month, Dr. Rashid Buttar posted on Twitter that covid-19 "was a planned operation" and shared an article alleging that most people who got the covid vaccine would be dead by 2025.
In a recent study, researchers investigate the possibility of using the thiazolide antiparasitic nitazoxanide for the treatment of COVID-19.
India continues to grapple with the coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, the country has reported over one million new cases for the past 28 days.
Ivermectin, a drug used to treat parasites such as scabies in humans and intestinal helminths in cattle, was screened in 2020 for activity against COVID-19. Laboratory tests suggested a weak effect on SARS-CoV-2 virus in a test tube but did not seem feasible in humans as the doses needed would be large.
New research describes the use of integrative bioinformatics analyses of transcriptomic profiles for COVID-19 therapeutics.
Researchers from the LSTM based Cochrane Infectious Disease Group explored whether community administration of ivermectin influences malaria transmission.
One of the pressing questions scientists are currently trying to answer is whether the current vaccines will remain effective against the emerging SARS-CoV-2 variants of concern. A new piece of research has been published in the journal Biomedicines, which discusses the knowledge we have gained thus far and the questions that researchers should address in future work.
Could a decades-old antidepressant be a secret weapon against covid? A few scientists think so, after two small studies showed that fluvoxamine, typically prescribed for obsessive-compulsive disorder, prevented serious illness in all participants who took the pills soon after developing symptoms.
Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication.
The clinical phenotype of COVID-19, caused by SARS-CoV-2, is remarkable for its wide range of severity among individual patients. Genetic variations are known to mediate part of these differences. To examine these differences, researchers in a new study used human induced pluripotent stem cells (iPSCs) from different genetically diverse individuals. These cells are used to model genetic disease since they contain the donor’s genetic information. Researchers use a panel of iPSCs from over 500 individuals. The researchers preferred undifferentiated iPSCs to reduce the time required to differentiate them, especially since infection is not always reliable.
McMaster University researchers are leading a large international study to test drugs to treat COVID-19 patients.
A team of researchers based in Peru and the U.S. recently examined the role of the anti-parasitic drug ivermectin in treating COVID-19.
A team of researchers at the Genomics Research Center, Academia Sinica, in Taiwan, evaluated the efficacy of 2,855 agents against SARS-CoV-2.
A small pilot study suggests that early administration of ivermectin can reduce viral loads and symptom duration in patients with mild COVID-19, which in turn could help reduce viral transmission.
A double-blind, randomized, placebo-controlled clinical trial has recently demonstrated that Ivermectin, an anti-parasitic drug, can reduce in-hospital mortality rate of COVID-19 patients.
Healthcare workers in tropical and sub-tropical settings where strongyloidiasis is prevalent or caring for patients who have travelled to such areas, need to maintain a high level of awareness about the use of corticosteroids, including when this class of anti-inflammatories is given to patients suspected of infection with SARS-CoV-2.
A team of researchers at the Institut Pasteur in France has found that ivermectin prevented clinical deterioration in infected animals. The drug also reduced the inflammatory cytokines, interleukin-6 and 10 (IL-6 and IL-10) in lung tissue, which leads to more favorable clinical outcomes in treated animals.
In 2019, 538.1 million people were treated for lymphatic filariasis (LF) in 38 countries that implemented mass drug administration (MDA) of populations at risk of the disease, as recommended by the World Health Organization (WHO).